As industry and the Food and Drug Administration prepare to begin discussions on regulatory structure that will guide the second decade of biosimilars in the US, agency officials appear willing to test the limits of FDA’s purview and push into product availability issues as part of an effort to encourage more sector growth.
Sarah Yim, director of the FDA’s Office of Therapeutic Biologics and Biosimilars (OTBB), said that “important factors affecting availability of...






